Anti-infective Drugs Market Definition
The anti-infective drugs market consists of sales of branded and generic anti-infective drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-infective drugs to treat microbial infections. The anti-infective drugs industry includes establishments that manufacture antibiotics to treat bacterial infections, anti-viral drugs to treat viral infections, anti-fungal drugs to treat fungal infections, anti-helminthic drugs to kill internal parasites, and antiprotozoal agents to treat protozoan infections.
Anti-infective Drugs Market Size
The global market for anti-infective drugs reached a value of nearly $88.5 billion in 2018, having grown at a compound annual growth rate (CAGR) of 7.0% since 2014.
Growth in the historic period resulted from rise in the incidence rates of infectious diseases, aging population and growth of emerging markets. Factors that negatively affected growth in the historic period were low returns of investment, pricing pressures from regulators and patent expiration of drugs.
Going forward, developments in drug discovery procedures, increase in sepsis prevalence and economic growth will drive growth. Factors that could hinder the growth of this market in the future include increasing antimicrobial resistance and reduction in free trade.
Anti-infective Drugs Market Drivers
The key drivers of anti-infective drugs market include:
Developments In Drug Discovery Procedures
The anti-infective drugs market is expected to benefit from the latest developments in drug discovery procedures such as stem cells and organ-on-chip (OOC) technologies. OOCs are micro-engineered biometric systems that simulate the activities, mechanics and physiological responses of organ systems. Drug trial processes such as target identification, validation, and screening are being executed through OOC and stem cell technologies. These technologies are considerably reducing the drug discovery costs and generating reliable predictions on drug efficiency and human safety. Another area of development is physiology-simulation modelling, in which the integrated physiology of the human organism, in both health and disease, is simulated through a computer program. Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early stages of the drug discovery process that are operational within hours, whereas traditional models take weeks to conduct simulations. The wide adoption of these technologies is expected to drive the anti-infective drugs market in the forecast period.
Anti-infective Drugs Market Restraints
The key restraints on the anti-infective drugs market include:
Supply Shortages Of Anti-Infective Drugs
The global anti-infective drugs market is facing supply shortages of anti-biotic drugs, especially antibiotics, due to the presence of few antibiotics manufacturers in the market. This can be attributed to low profits margins in the industry and exit strategies adopted by the market players. This has given rise to heavy reliance on a few manufacturers, leading to shortages of antibiotics supply, thus restraining the market’s growth. In 2015, a commonly prescribed antibiotic, benzathine penicillin G (BPG), was unavailable in 39 out of 114 countries covered in the World Health Organization’s (WHO) study. Similarly, an explosion at a Chinese manufacturing facility in 2016, the only facility globally producing the active pharmaceutical ingredient (API) needed for manufacturing the piperacillin-tazobactam, caused a global shortage of this antibiotic drug. Additionally, major antibiotics companies such as Novartis, AstraZeneca, Sanofi, and Allergan are shutting down their antibiotic research operations due to the lack of profitability, which further sets a negative impact of the drugs shortage in the long run in the anti-infective drugs market.
Anti-infective Drugs Market Trends
Major trends influencing the anti-infective drugs market include:
Strategic Collaborations And Agreements
Companies in the anti-infective drugs market are strategically partnering and collaborating with other companies to broaden their product portfolios. In December 2014, Chimerix, Inc. and ContraVir Pharmaceuticals, Inc. entered into a strategic collaboration for the clinical development and commercialization of antiviral drug CMX157. In December 2016, Evotec AG, a biotechnology company, entered into a strategic alliance with Forge Therapeutics, Inc., to advance its novel Gram-negative antibiotic program targeting LpxC for the treatment of bacterial infections. In October 2018, AiCuris, a leading pharmaceutical company in the discovery and development of innovative drugs targeting infectious diseases, and Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery of novel therapeutics, entered into a collaboration to develop novel anti-infective drugs.
Global Research Initiatives And Funding
Pharmaceutical companies and federal governments are increasingly working together in partnerships and collaborations to provide funding and implement incentive programs for the research and development (R&D) of anti-infective drugs. These partnerships provide financial and technical assistance across different clinical development phases to pharmaceutical companies. Programs such as the Innovative Medicines Initiative’s (IMI’s) New Drugs for Bad Bugs (ND4BB) program, Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), and Biomedical Advanced Research and Development Authority’s (BARDA) Broad Spectrum Antimicrobials Program have been implemented for the development of novel antibiotics by focusing on R&D gaps. Similarly, Global Antibiotic Research and Development Partnership (GARDP) was set up by the World Health Organization (WHO) and the Drugs for Neglected Diseases Initiative (DNDi) in May 2016. This R&D initiative focuses on the development of new or improved antibiotic treatments.
Opportunities And Recommendations In The Anti-infective Drugs Market
Opportunities – The top opportunities in the global anti-infective drugs market will arise in the antivirals segment which will gain $14.11 billion of global annual sales by 2022. The anti-infective drugs market size will gain the most in the USA at $10.55 billion. Market-trend-based strategies for the anti-infective drugs market include entering into collaborative partnerships to broaden product portfolios, focusing on research and development on drug resistance, adopting 3D printing technology to reduce pre-clinical costs. Player-adopted strategies in the anti-infective drugs market include broadening the product portfolios through strategic collaborations and acquisitions, and focusing on new drug development through investments in research and development.
Recommendations – To take advantage of these opportunities, The Business Research Company recommends the anti-infective drugs manufacturing companies to expand in emerging markets, invest in research and development to combat drug resistance and development of new anti-infective drugs, adopt skimmed and competitive pricing strategies, and integrate big data analytics to manage clinical trial data, among other strategies.
Anti-infective Drugs Market Segmentation
The anti- infective drugs market is segmented by type of product.
By Product Type-
The anti-infective drugs market can be segmented by product type into
Antivirals had the highest growth rate of nearly 7.4% during the historic period. The fastest market growth can be attributed to rapid increase in the access to antiviral treatment of sexually transmitted diseases such as Hepatitis B and HIV/AIDS.
- a) Antibiotics
- b) Antivirals
- c) Antifungals
- d) Others (Anthelminthic, Antiprotozoal)
The antibiotics market can be sub-segmented by product type into
The antivirals market can be sub-segmented by therapeutic type into
- a) ß-Lactams
- b) Quinolones
- c) Macrolides
- d) Aminoglycosides
- e) Others
The antifungals market can be sub-segmented by product type into
- a) HIV AIDS Therapeutics
- b) Hepatitis Therapeutics
- c) Herpes Therapeutics
- d) Influenza Therapeutics
The anti-infective drugs market is segmented into
North America was the largest market for anti-infective drugs, accounting for a 47.7% of the global market in 2018. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, Africa and Middle East will be the fastest growing regions in this market.
- o North America
- o Western Europe
- o Asia Pacific
- Hong Kong
- New Zealand
- South Korea
- o Eastern Europe
- Czech Republic
- o South America
- o Middle East
- Saudi Arabia
- o Africa
- South Africa
Anti-infective Drugs Market Competitive Landscape
Major Competitors are:
Other Competitors Include:
- · Gilead Sciences
- · GlaxoSmithKline plc
- · Merck & Co.
- · Teva Pharmaceutical Industries Ltd.
- · Johnson & Johnson
- • Boehringer Ingelheim GmbH
- • Pfizer
- • Mylan N.V.
- • Bristol-Myers Squibb
- • F. Hoffmann-La Roche Ltd
- • Shanghai Pharmaceuticals
- • Shanghai Fosun Pharmaceutical
- • Cipla
- • Dr. Reddy’s Laboratories Ltd.
- • Sun Pharma
- • Takeda Pharmaceutical Company Ltd.
- • Otsuka Pharmaceutical Co. Ltd.
- • Daiichi Sankyo
- • Roche
- • Novartis
- • Sanofi
- • AstraZeneca
- • Novo Nordisk
- • Bayer
- • Sotex
- • Microgen
- • Pharmstandard
- • STADA CIS Russian Holding
- • Amgen
- • AbbVie
- • Eli Lilly and Company
- • Q Pharm
- • 3M Pharmaceuticals
- • União Quimica
- • Ache
- • EMS Pharma
- • Hypermarcas
- • Medley
- • Teuto Brasileiro
- • Biolab Farmaceutica
- • Cristalia
- • Libbs
- • Saudi Pharmaceutical Industries
- • Gulf Pharmaceutical Industries (Julphar)
- • Adcock Ingram
- • Aspen